Overexpression of TopBP1, a canonical ATR/Chk1 activator, paradoxically hinders ATR/Chk1 activation in cancer

Kang Liu, Joshua D. Graves, Fang-Tsyr Lin, and Weei-Chin Lin

For correspondence: Weei-Chin Lin, weeichil@bcm.edu.
Present address for Joshua D. Graves: Centers for Disease Control and Prevention, Atlanta, GA, USA.

Topoisomerase IIβ-binding protein 1 (TopBP1) is involved in cellular replication among other functions and is known to activate ATR/Chk1 during replicative stress. TopBP1 is also expressed at high levels in many cancers. However, the impact of TopBP1 overexpression on ATR/Chk1 activation and cancer development has not been investigated. Here we demonstrate that the degree of ATR/Chk1 activation is regulated by TopBP1 in a biphasic, concentration-dependent manner in a non-transformed MCF10A cell line and several cancer cell lines, including H1299, MDA-MB468, and U2OS. At low levels, TopBP1 activates ATR/Chk1, but once TopBP1 protein accumulates above an optimal level, it paradoxically leads to lower activation of ATR/Chk1. This is due to the perturbation of ATR–TopBP1 interaction and ATR chromatin loading by excessive TopBP1. Overexpression of TopBP1 thus hinders the ATR/Chk1 checkpoint response, leading to the impairment of genome integrity as demonstrated by the cytokinesis-block micronucleus assay. In contrast, moderate depletion of TopBP1 by shRNA in TopBP1-overexpressing cancer cells enhanced ATR/Chk1 activation and S-phase checkpoint response after replicative stress. The clinical significance of these findings is supported by an association between TopBP1 overexpression and genome instability in many types of human cancer. Taken together, our study illustrates an unexpected relationship between the levels of TopBP1 and the final functional outcome and suggests TopBP1 overexpression as a new mechanism directly contributing to genomic instability during tumorigenesis.
**Biphasic control of ATR/Chk1 by TopBP1**

TopBP1. Indeed, TopBP1 overexpression is associated with genome instability in many types of cancer.

**Results**

The relationship between TopBP1 levels and the amplitude of ATR/Chk1 activation is a biphasic (hormesis) concentration-dependent response

To determine how TopBP1 protein levels affect the intensity of Chk1 activation, we first knocked down TopBP1 in MDA-MB468, a triple-negative breast cancer cell line, and then reconstituted TopBP1 to different expression levels by infecting cells with a recombinant adenovirus Ad-TopBP1 at various multiplicity of infection (MOI). The total amounts of adenovirus were kept constant by adding a recombinant adenovirus Ad-CMV that harbors an empty vector. Cells were then treated with hydroxyurea (HU), a replication stress-inducing drug, and immunoblotting was performed to determine the levels of phospho-Chk1 (Ser345), which serves as a readout of Chk1 activity. Consistent with our prior report (12), the phosphorylation of Chk1 was almost completely blocked when TopBP1 was fully depleted but was gradually induced by adding TopBP1 in a concentration-dependent manner. It is surprising that, when cells were infected with Ad-TopBP1 at an MOI of 400, TopBP1 expression reached a level higher than that in control cells and the level of phosphorylated Chk1 dropped to a level significantly lower than that in the HU-treated shScr control cells (Fig. 1A). This phenomenon was also observed in another cancer cell line, H1299 (Fig. 1B). These data suggest that, although TopBP1 is essential for Chk1 phosphorylation in response to DNA damage, when TopBP1 is accumulated beyond an optimal level, it could instead have an inhibitory effect on Chk1 activation. This biphasic (hormesis or inverted U) dose response described in toxicology is characterized by a low-dose stimulation and high-dose inhibition to chemicals of interest, i.e., existence of a sweet spot beyond which more chemicals paradoxically lead to a declining response. Many cancer cells express high levels of TopBP1 in part due to deregulation of the Rb/E2F pathway (15–17). If the levels of TopBP1 are higher than the optimal level for ATR activation, these cancer cells may, to some extent, become defective in checkpoint response to replicative stress. To determine whether the levels of TopBP1 in those TopBP1-depleted cells infected with high titers of Ad-TopBP1 were still within physiological ranges compared with the endogenous TopBP1 protein levels in other cancer cells and tissues, we compared TopBP1 expression among these cells and three commonly used cancer cell lines, including OVCAR3, C33A, and K562 cells (Fig. 1C, left panel). We also compared their levels with the endogenous TopBP1 levels in eight primary breast cancer fresh-frozen samples that have
been shown to express high levels of TopBP1 in a prior study (15) (Fig. 1C, right two panels). It appears that the levels of TopBP1 in the Ad-TopBP1-infected MDA-MB468-shTopBP1 cells were either comparable with or within twofold higher or lower than those expressed in the three cancer lines or tumor tissues. Thus, the levels of TopBP1 that can cause a paradoxically inhibitory effect on Chk1 activation are within the physiological range seen in many cancer cells.

**A modest reduction of TopBP1 expression in MDA-MB468 cells paradoxically potentiates ATR/Chk1 response, whereas highly efficient knockdown of TopBP1 blocks ATR/Chk1 activation**

The data in Figure 1, A and B suggest that the effect of TopBP1 on p-Chk1 activation is biphasic concentration dependent, i.e., an optimal concentration of TopBP1 is required for maximal ATR/Chk1 response. To further investigate this possibility, we stably knocked down TopBP1 to various degrees in MDA-MB468 cells that express TopBP1 at the highest level among a panel of breast cancer cell lines (18). We treated these stable cells with HU for 2 h and then compared the Chk1 phosphorylation by immunoblotting. Indeed, knockdown of TopBP1 to a mild to moderate degree (30%–50% knockdown in shTopBP1-1A and 1B cells) enhanced Chk1 activity after DNA replication stress, whereas an almost complete knockdown of TopBP1 (80%–100% knockdown in shTopBP1-2 and 3 cells) greatly eliminated Chk1 phosphorylation (Fig. 2A). We also performed a time course experiment by treating these stable cells with HU for 1, 2, or 5 h and obtained the same conclusion (Fig. 2B). These data suggest that, although TopBP1 is required for ATR/Chk1 activation in response to replicative stress, depletion of TopBP1 to a moderate level in cancer cells that express high

![Figure 2](image.png)
levels of TopBP1, such as MDA-MB468, can actually induce a stronger ATR/Chk1 response to replicative stress.

To further support this notion, we reconstituted TopBP1 in one of the MDA-MB468 cell lines that showed modest knockdown of TopBP1 (shTopBP1-1A cells) by Ad-TopBP1 infection at various MOIs, such that their TopBP1 expression was lower or close to that in the shScr control cells. We found that modest (less than 50%) depletion of TopBP1 enhanced Chk1 phosphorylation induced by HU treatment for 5 h; nevertheless, reconstitution of TopBP1 to the level comparable with that in the control cells could reverse this effect (Fig. 2C). Taken together, these results indicate that an optimal level of TopBP1 is required for ATR/Chk1 activation. In cancer cells, the levels of TopBP1 affect the amplitude of Chk1 activation in response to DNA damage. When TopBP1 levels reach above an optimal level, it can in fact paradoxically decrease the degree of Chk1 activation.

**High levels of TopBP1 perturb its binding to ATR and decrease the levels of chromatin-associated ATR**

To study the underlying molecular mechanism by which high levels of TopBP1 lead to declined Chk1 activity during DNA damage, we first tested whether highly expressed TopBP1 could interfere with its binding to chromatin, thereby inhibiting the TopBP1/ATR/Chk1 pathway. To test this possibility, we infected TopBP1-depleted H1299 cells with Ad-TopBP1 at various MOIs and then treated cells with HU, followed by chromatin fractionation (fractions III + IV representing chromatin fractions (19)). As shown in Figure 3A, the effect of TopBP1 on enhancing HU-induced Chk1 activation started to decline when the MOI of Ad-TopBP1 reached 400. Under this condition, TopBP1 could still tightly bind to chromatin. Since phosphorylation of TopBP1 at the S1159 residue by Akt can induce TopBP1 oligomerization and...
hamper its ability to activate ATR (10), we next examined if S1159 phosphorylation of TopBP1 was increased when the levels of p-Chk1 started to decline. However, we did not see an increase of pS1159-TopBP1 levels by Ad-TopBP1 infection at MOI 400 versus 200, despite a decrease of p-Chk1 in cells infected at MOI 400 (Fig. 3B). This result excludes the possibility of Akt regulation in this process. Increasing the levels of TopBP1 also did not significantly alter ATR expression. Since the interaction between TopBP1 and ATR is required for TopBP1 to activate ATR, we next infected

Figure 4. TopBP1 overexpression inhibits chromatin recruitment of the ATR–ATRIP complex and the interaction of TopBP1 with ATR–ATRIP upon hydroxyurea treatment. U2OS or MCF10A cells were infected with Ad-CMV or Ad-TopBP1 at the indicated MOI. Cells were then treated with HU (2 mM), followed by either chromatic fractionation as described in Figure 3A (A and B) or coimmunoprecipitation as described in Figure 3C (C and D). The relative intensities of immunoprecipitated proteins in (C) were quantified using ImageJ software and were normalized to the immunoprecipitated TopBP1 in the same samples.
TopBP1-depleted H1299 cells with Ad-TopBP1 at various MOIs and then examined this binding following HU treatment for 5 h. As shown in Figure 3C, more ATR was coimmunoprecipitated with TopBP1 when TopBP1 levels were increased by Ad-TopBP1 infection from an MOI of 100 to 200, coinciding with the increased Chk1 phosphorylation. However, this interaction was decreased when the Ad-TopBP1 titer was increased to an MOI of 400 (Fig. 3C), coinciding with the declined Chk1 phosphorylation (Fig. 3D). In contrast, the association of TopBP1 with E2F1 or BACH1 was increased by elevating the titer of Ad-TopBP1 from an MOI of 100 to 400 (Fig. 3C). Moreover, chromatin binding assay demonstrated that ATR binding to chromatin was significantly decreased when TopBP1 was highly expressed by Ad-TopBP1 infection at an MOI of 400, concurrent with an increase of chromatin-associated TopBP1 and a declining level of Chk1 phosphorylation (Fig. 3D). These results could also be reproduced in two additional cell lines, U2OS and MCF10A, where expression of TopBP1 by Ad-TopBP1 caused biphasic changes of both Chk1 activation and ATR–ATRIP recruitment to chromatin (Fig. 4, A and B). In contrast, RPA recruitment to chromatin was not affected by TopBP1. On the other hand, Rad9 recruitment was slightly inhibited by TopBP1 in a dose-dependent, but not biphasic, manner. Consistently, co immunoprecipitation showed that high levels of TopBP1 paradoxically inhibited its interaction with ATR–ATRIP complex and to a lesser degree with Rad9, but not with BACH1, E2F1, or RPA (Fig. 4, C and D). Collectively, these data suggest that, when TopBP1 is expressed above an optimal level, it can paradoxically inhibit Chk1 activation after replicative stress through the inhibition of its interaction with ATR–ATRIP and interference of ATR–ATRIP recruitment to chromatin.

**BRCT1/2/3, but not S1159, phosphorylation of TopBP1 is required for the paradoxical inhibition of ATR by TopBP1 overexpression**

TopBP1 and ATR–ATRIP are recruited to stalled replication forks through binding to RPA-ssDNA (6). Too many TopBP1 molecules may saturate the available RPA-coated ssDNA on stalled replication forks and therefore prevent ATR–ATRIP recruitment. Since TopBP1 binds to RPA-ssDNA through its BRCT2 domain (6), we next investigated if overexpression of a TopBP1 mutant lacking BRCT2 fails to inhibit ATR/Chk1 activation. Indeed, in contrast to the wildtype TopBP1, a TopBP1-ΔBRCT1/2/3 mutant did not elicit the biphasic p-Chk1 effect after HU treatment (Fig. 5A). Previously we have shown that Akt-mediated phosphorylation of TopBP1 at S1159 induces TopBP1 oligomerization and inhibits its ability to activate ATR (10). However, a TopBP1-S1159A mutant that cannot be phosphorylated by Akt was capable of promoting the biphasic p-Chk1 response following HU treatment (Fig. 5B), indicating that Akt-induced oligomerization of TopBP1 is not involved in this process.

**A modest depletion of TopBP1 in cancer cells enhances S-phase checkpoint in response to HU treatment**

When cells are exposed to DNA replicative stress like HU, the cell cycle checkpoint will be activated and DNA synthesis will be halted to allow cells to repair the damaged DNA before it moves to the next phase of cell cycle. Based on the results shown above, we predicted that inhibition of HU-induced Chk1 activation by excessively expressed TopBP1 would lead to the impairment of checkpoint activation and cell cycle arrest. To investigate the physiological role of TopBP1 in the checkpoint response in cancer cells

---

**Figure 5. The effect of TopBP1 overexpression on the inhibition of HU-induced Chk1 activation requires its BRCT1/2/3 domains but not Akt-mediated S1159 phosphorylation.** A, H1299-shTopBP1 cells were transfected with different amounts of plasmid expressing either WT TopBP1 or a deletion mutant of TopBP1 (ΔBRCT1/2/3 or FLAG-BRCT6/7/8). After HU treatment (2 mM) for 2 h, immunoblotting was performed to detect the expression of p-Chk1, Chk1, WT, or mutant TopBP1. B, H1299-shTopBP1 cells were infected with Ad-CMV and/or Ad-TopBP1 (WT or S1159A) at the indicated MOI. Cells were treated with HU (2 mM), followed by immunoblotting as described above. HU, hydroxyurea.
Figure 6. Modest depletion of TopBP1 in the cells highly expressing TopBP1 enhances S-phase checkpoint response to HU treatment. A, BrdU incorporation assay was performed in MDA-MB468 stable cells with modest or high-efficient knockdown of TopBP1. Cells were treated with HU (2 mM) or DMSO for 2 h, followed by labeling with BrdU (10 μM) for another 2 h. Cells were then collected and fixed for anti-BrdU antibody staining. Flow cytometric analysis was performed to quantify BrdU incorporation in at least 10,000 cells per sample. Data shown represent means ± SD from three biological replicates. The p values are based on a two-tailed t test. The effect of TopBP1 knockdown was verified by immunoblotting. B, representative profiles of BrdU incorporation described in (A). HU, hydroxyurea.
expressing high levels of TopBP1, we next performed BrdU incorporation assay to examine how a modest (less than 50%) or high (more than 90%) degree of TopBP1 depletion may affect DNA synthesis after HU treatment in TopBP1-depleted MDA-MB468 stable cells. The incorporated BrdU was both quantified by flow cytometry (Fig. 6, A and B) and visualized under fluorescence microscope (see Fig. S1). We found that modest depletion of TopBP1 did not affect BrdU incorporation in the absence of HU but potentiated the reduction of BrdU incorporation after HU treatment (Fig. 6, A and B), suggesting that reduction of TopBP1 may potentiate the S-phase checkpoint response in MDA-MB468 cells. In parallel, we also measured the response in high-efficient TopBP1 knockdown MDA-MB468 cells (Fig. 6A, right panel). As expected, the BrdU incorporation was inhibited by high-efficient TopBP1 depletion even in the absence of HU. However, there was no significant change in BrdU incorporation between shScr control cells and the high-efficient TopBP1 knockdown cells after HU treatment, consistent with a reduction of p-Chk1 activation in these shTopBP1 cells (Fig. 2A, shTopBP1-2 and shTopBP1-3). Thus, in cancer cells with high levels of endogenous TopBP1, modest but not high-efficient knockdown of TopBP1 can render cells more responsive to replicative stress to halt DNA synthesis and allow repair of DNA damage as in normal cells.

**TopBP1 overexpression renders cells more sensitive to replication stress**

Inhibition of ATR sensitizes cells to replication stressors, such as HU and aphidicolin. To address the biphasic regulation of ATR activity by TopBP1, we next reconstituted TopBP1 at different levels in TopBP1-depleted MDA-MB468 cells and assessed cell viability after treatment with HU (Fig. 7A) or aphidicolin (Fig. 7B). Indeed, knockdown of TopBP1 increased cell sensitivity to HU or aphidicolin, and this effect could be rescued by adding Ad-TopBP1 back at MOI 100 or 200. However, when TopBP1 was reconstituted with Ad-TopBP1 at MOI 400, this rendered cells more sensitive to HU or aphidicolin, consistent with its effect on ATR inhibition.

**High levels of TopBP1 are associated with genome instability in cancer**

We next examined whether TopBP1 overexpression affects genome integrity using the cytokinesis-block micronucleus assay (20, 21), which has been well established for the measurement of genomic instability. The data showed that overexpression of TopBP1 in MCF10A significantly increased the frequency of micronuclei-containing binucleated cells after a short treatment with doxorubicin (Fig. 8). This result provides evidence that overexpression of TopBP1 in normal cells can impair their ability to maintain genome stability, consistent with their effect on ATR/Chk1 inhibition.

To obtain further evidence for the association between high TopBP1 expression and genome instability in cancer, we explored several cancer genome databases. In both prostate and uterine endometrioid carcinoma The Cancer Genome Atlas Program (TCGA) cohorts (22, 23), the patients have been clustered based on the somatic copy number alterations (SCNAs). We analyzed TopBP1 expression in the copy number alterations (CNAs) subtypes that are already grouped in both studies (Fig. 9, A and B, right panel).
panels). As a positive control for the clustering, we also compiled the fraction of genome altered (percentage of genome affected by copy number gains or losses; cBioportal) in each sample in these clusters (Fig. 9, A and B, left panels). Indeed, high TopBP1 expression is associated with more SCNA in prostate cancer (Fig. 9A). In TCGA uterine corpus endometrioid carcinoma, high levels of TopBP1 are also significantly found in cluster 4, which is characterized by a very high degree of SCNAS (Fig. 9B) (23).

We next used the fraction of genome altered in each sample as an index for genomic instability to investigate its correlation with TopBP1 expression across all cancer types in PanCancer TCGA datasets. We found very good correlations between TopBP1 expression and Fraction Genome Altered in the majority of cancer types in PanCancer TCGA (Fig. 9, C–I) and METABRIC breast dataset (Fig. 9J), suggesting that this association is a general phenomenon among different cancer types.

Discussion

A full function of ATR/Chk1 activation is of paramount importance for genome stability. Although a role for TopBP1 in ATR/Chk1 activation in normal cells is well established, the significance of TopBP1 overexpression in ATR/Chk1 activation in cancer cells expressing high levels of TopBP1 has not been investigated. Here we uncover an unexpected biphasic concentration-dependent response of ATR/Chk1 activation controlled by the levels of TopBP1 in cancer cells. By reconstitution of TopBP1 in the TopBP1-deleted cancer cells with different MOI of Ad-TopBP1, we demonstrate that low levels of TopBP1 stimulate, but high levels of TopBP1 inhibit, Chk1 activation. The mechanistic analysis further reveals that, when TopBP1 accumulates above an optimal level, it can paradoxically decrease the chromatin-associated ATR and its interaction with ATR, resulting in reduced ATR/Chk1 activation. The result is very relevant in cancer, since a modest reduction of TopBP1 level in cancer cells that highly express TopBP1 can enhance S-phase checkpoint response to replicative stress. Thus, many cancer cells may not have full functionality of ATR response owing to overexpression of TopBP1. Therapy that can reduce TopBP1 levels might refortify the checkpoint response in many cancers that overexpress TopBP1.

High TopBP1 expression may contribute to tumor development by reducing the strength of ATR/Chk1 activation. A complete deficiency of Chk1 is lethal, whereas conditional heterozygous knockout of Chk1 in mouse mammary glands causes inappropriate S phase entry, accumulation of DNA damage, and premature mitosis, demonstrating Chk1 as a haploinsufficient tumor suppressor (24). Thus, the checkpoint function of Chk1 is dependent on its full expression. Similar to Chk1, ATR also acts as a haploinsufficient tumor suppressor (25). Hence, the attenuation of ATR/Chk1 activation by TopBP1 overexpression is expected to contribute to tumorigenesis through genomic instability. In fact, high levels of TopBP1 expression are strongly associated with genome instability in many types of cancer (Fig. 9).

Of interest, the biphasic pattern of interaction is only seen in the TopBP1–ATR complex but not in the complex of TopBP1 with E2F1, BACH1, or RPA (Figs. 3C and 4, C and D). As more TopBP1 is overexpressed, there are more TopBP1–E2F1 and TopBP1–BACH1 complexes. This result demonstrates that the interaction of TopBP1 with ATR is distinct from its binding to either E2F1 or BACH and is
more dependent on appropriate and modest levels of TopBP1. As TopBP1 expression is increased, the chromatin-bound TopBP1 is also increased (Figs. 3A and 4A and B). Since both TopBP1 and ATR–ATRIP are recruited to stalled replication forks through binding to RPA-coated ssDNA (6), when the chromatin-bound TopBP1 accumulates above an optimal level, too many TopBP1 molecules may saturate the available RPA-coated ssDNA on a stalled replication fork and therefore prevent ATR–ATRIP recruitment. This possibility is supported by that TopBP1–ΔBRCT1/2/3 does not exhibit the biphasic response (Fig. 5A). In addition, binding to both 9-1-1 and ATR–ATRIP is required for TopBP1 to activate ATR (8). Excessive TopBP1 on stalled replication forks may prevent TopBP1 from forming proper complexes with both 9-1-1 and ATR–ATRIP (Fig. 4, C and D) simultaneously and presenting its ATR-activating domain for ATR activation. Future investigation will be needed to elucidate the structural basis of these interactions.

**Experimental Procedures**

**Cell culture**

MDA-MB468, H1299, C33A, and K562 cells were maintained in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine serum. OVCAR-3 cells were maintained in RPMI-1640 medium supplemented with 10% fetal bovine serum. MCF10A were maintained in Dulbecco’s modified Eagle’s medium/F12 supplemented with horse serum (5%), epidermal growth factor (20 ng/ml), hydrocortisone (0.5 μg/ml), cholera toxin (100 ng/ml), and insulin (10 μg/ml). Penicillin (50 IU/ml) and streptomycin (50 μg/ml) were added to all culture media. All cells were grown in a humidified incubator at 37 °C with 5% CO2 and 95% air.
Establishment of stable cell lines

MDA-MB468 and H1299 cells were infected with lentivirus harboring a scrambled shRNA or a TopBP1 shRNA (16) followed by selection with puromycin (2 μg/ml) to establish stable cell lines expressing a scrambled shRNA (shScr) or a TopBP1 shRNA (shTopBP1). The effect of knockdown was confirmed by Western blotting using an antibody specific to TopBP1.

Immunoprecipitation and Western blot analysis

Immunoprecipitation was performed by incubating equal amounts of cell lysates with an anti-TopBP1 mouse monoclonal antibody or control mouse IgG and then with protein A/G agarose beads (from GenDepot) for 16 h at 4 °C. After three washes, immunoprecipitates were fractionated by SDS-PAGE and electrotransferred to Imobilon-P membrane (Millipore). Immunoblotting was performed with appropriate antibodies. Antibody specific to E2F1 (C-20 or KH-95), Chk-1 (G-4), Rad9 (M-389), or GAPDH (6C5) was from Santa Cruz Biotechnology. Anti-TopBP1 mouse monoclonal antibody was from BD Transduction Laboratories. Anti-TopBP1 (BL893) rabbit polyclonal antibody was from Bethyl Laboratories. Anti-phospho-TopBP1 (S1159) antibody was from Abgent. Antibody specific to p-Chk1(S345), ATR, ATRIP, BACH1/BRIP1, RPA32, or Histone H3 was from Cell Signaling.

Chromatin binding assay

The assay was performed as described (10). Briefly, the infected cells were first resuspended for 5 min on ice in 150 μl fractionation buffer (50 mM Hepes, pH 7.5, 150 mM NaCl, 1 mM EDTA) containing 0.2% NP-40, supplemented with protease inhibitors as described. Following centrifugation at 1000 g for 5 min, the supernatant was collected (fraction I), and pellets were washed with the same buffer. The wash was collected (fraction II), and the nuclear pellets were further extracted for 40 min on ice with 150 μl fractionation buffer containing 0.5% NP-40. The extracts were clarified by centrifugation at 16,000g for 15 min (fraction III). The pellets were finally lysed in 150 μl of 10% SDS-PAGE sample buffer and boiled for 5 min (fraction IV). The aliquots of each fraction derived from equivalent cell numbers were collected. In this study, the combined aliquots from fraction (I+II) and fraction (III+IV) were separated on 10% SDS-PAGE, and Western blotting was carried out.

Bromodeoxyuridine incorporation assay and flow cytometry

For flow cytometric analysis, cells were labeled with 5-bromo-2-deoxyuridine (BrdU, 10 μM) for 2 h and then fixed with 70% ethanol. Cells were treated with 2 N HCl/Triton X-100 for 30 min and then neutralized with 0.1 M sodium tetraborate, pH 8.5. Cells were then stained with FITC-conjugated anti-BrdU antibody (BD Biosciences) and propidium iodide, followed by flow cytometry. At least 10,000 cells were analyzed for each sample. All experiments were performed in at least triplicates. For microscopic analysis, cells were labeled with BrdU for 6 h. After fixation with 4% formaldehyde, the incorporated BrdU was detected with an anti-BrdU antibody (Ab-3, Calbiochem) followed by Texas Red X-conjugated secondary antibody (Invitrogen). Nuclei were stained with Hoechst 33258 dye. Images were captured with a Zeiss fluorescence microscope (Axio Observer Inverted Microscope).

Statistical analysis

Two-tailed t test was performed to compare two experimental groups. One-way ANOVA was used to determine whether three or four groups are statistically different from each other. Data were presented as means ± SD from at least three biological replicates. p Values less than 0.05 were considered statistically significant. RNA sequencing (RNA-Seq) gene expression data, CNA clustering, and fraction of genome altered in TCGA database were extracted from cBioportal server (https://cbioportal.org/). Gene expression and CNA data in the METABRIC breast cancer dataset were also extracted from cBioportal server. The fraction of genome altered in each sample was then calculated from the META BRIC CNA dataset based on the fraction of 22,544 genes/genomic loci with copy number gains or losses. Pearson correlation coefficients were calculated to evaluate correlations.

MTT assay

MTT assay was used to determine cell viability. Cells were seeded in 96-well plates at 5000 to 10,000 cells per well for 24 h, followed by indicated treatment for another 48 h. Cells were then washed and incubated with MTT solution (Thiazolyl blue tetrazolium bromide, 5 mg/ml) (Sigma) at 37 °C for 3 to 4 h. After the removal of medium and MTT solution, 100 μl DMSO was added to each well. The absorbance was read at 570 nm on a plate reader (BioTek Synergy HT). Each experiment was performed at least in triplicates.

Cytokinesis-block micronucleus assay

MCF10A were infected with Ad-CMV or Ad-TopBP1 at MOI 100. Twenty-four hours later, cells were split into six-well plates. On the next day, cells were treated with doxorubicin at increasing doses for 4 h. Media were then removed and fresh medium containing cytochalasin B (3 μg/ml) was added for another 24 h. Cells were then fixed with 4% formaldehyde, and nuclei were stained with Hoechst 33258 dye. Images were captured with a Zeiss fluorescence microscope (Axio Observer inverted microscope). At least 1000 binucleated cells per group were scored. The frequency of micronuclei-containing binucleated cells among all binucleated cells was calculated.

Data availability

All data are presented in the article.

Supporting information—This article contains supporting information.

Acknowledgments—We acknowledge the support from the Cytometry and Cell Sorting Core (NIAID P30AI036211, NCI P30CA125123, and NCRR S10RR024574) at Baylor College of Medicine.
Biphasic control of ATR/Chk1 by TopBP1

Author contributions—K. L. and W.-C. L. conceived the project and designed research; K. L. performed most experiments; J. D. G. performed BrdU/PI flow cytometry analysis; W.-C. L. performed bioinformatics analyses; K. L., J. D. G., F.-T. L., and W.-C. L. analyzed data; F.-T. L. and W.-C. L. contributed reagents/analytic tool, and K. L., F.-T. L., and W.-C. L. wrote the paper. W.-C. L. and F.-T. L. acquired funding.

Funding and additional information—This work was supported by National Institutes of Health Grants R01CA100857, Rivkin Center for Ovarian Cancer Pilot Award (to W.-C. L.) and R01CA203824 and Department of Defense Grants, W81XWH-18-1-0329 and W81XWH-19-1-0369 (to W.-C. L. and F.-T. L.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Conflict of interest—The authors declare that they have no conflicts of interest with the contents of this article.

Abbreviations—The abbreviations used are: AAD, ATR-activating domain; ATR, Ataxia telangiectasia mutated and Rad3 related; ATRIP, ATR-interacting protein; BRCT, BRCA1 carboxyl-terminal; CNA, copy number alteration; HU, hydroxyurea; MOI, multiplicity of infection; RPA, replication protein A; SCNA, somatic copy number alteration; TopBP1, topoisomerase IIβ-binding protein 1; TCGA, The Cancer Genome Atlas Program.

References
1. Kumagai, A., Lee, J., Yoo, H. Y., and Dunphy, W. G. (2006) TopBP1 activates the ATR-ATRIP complex. Cell 124, 943–955
2. Bass, T. E., Luzwick, J. W., Kavanaugh, G., Carroll, C., Dungrawala, H., Glick, G. G., Feldkamp, M. D., Putney, R., Chazin, W. J., and Cortez, D. (2016) ETAA1 acts at stalled replication forks to maintain genome integrity. Nat. Cell Biol. 18, 1185–1195
3. Haahr, P., Hoffmann, S., Tollenæere, M. A., Ho, T., Toledo, L. I., Mann, M., Bekker-Jensen, S., Raschle, M., and Mailand, N. (2016) Activation of the ATR kinase by the RPA-binding protein ETAA1. Nat. Cell Biol. 18, 1196–1207
4. Lee, Y. C., Zhou, Q., Chen, J., and Yuan, J. (2016) RPA-binding protein ETAA1 is an ATR activator involved in DNA replication stress response. Curr. Biol. 26, 3257–3268
5. Wardlaw, C. P., Carr, A. M., and Oliver, A. W. (2014) TopBP1: A BRCT-scaffold protein functioning in multiple cellular pathways. DNA Repair (Amst.) 22, 165–174
6. Acevedo, J., Yan, S., and Michael, W. M. (2016) Direct binding to replication protein A (RPA)-coated single-stranded DNA allows recruitment of the ATR activator TopBP1 to sites of DNA damage. J. Biol. Chem. 291, 13124–13131
7. Delacroix, S., Wagner, J. M., Kobayashi, M., Yamamoto, K., and Karnitz, L. M. (2007) The Rad9-Hus1-Rad1 (9-1-1) clamp activates checkpoint signaling via TopBP1. Genes Dev. 21, 1472–1477
8. Yan, S., and Michael, W. M. (2009) TopBP1 and DNA polymerase alpha-mediated recruitment of the 9-1-1 complex to stalled replication forks: Implications for a replication restart-based mechanism for ATR checkpoint activation. Cell Cycle 8, 2877–2884
9. Liu, K., Paik, J. C., Wang, B., Lin, F. T., and Lin, W. C. (2006) Regulation of TopBP1 oligomerization by Akt/PKB for cell survival. EMBO J. 25, 4795–4807
10. Liu, K., Graves, J. D., Scott, J. D., Li, R., and Lin, W. C. (2013) Akt switches TopBP1 function from checkpoint activation to transcriptional regulation through phosphoryser binding-mediated oligomerization. Mol. Cell Biol. 33, 4685–4700
11. Liu, K., Graves, J. D., Lee, Y. J., Lin, F. T., and Lin, W. C. (2020) Cell cycle-dependent switch of TopBP1 functions by Cdk2 and Akt. Mol. Cell Biol. 40
12. Liu, K., Lin, F. T., Graves, J. D., Lee, Y. J., and Lin, W. C. (2017) Mutant p53 perturbs DNA replication checkpoint control through TopBP1 and Treslin. Proc. Natl. Acad. Sci. U. S. A. 114, E3766–E3775
13. Liu, K., Luo, Y., Lin, F. T., and Lin, W. C. (2004) TopBP1 recruits Brg1/Brm to repress E2F1-induced apoptosis, a novel pRb-independent and E2F1-specific control for cell survival. Genes Dev. 18, 673–686
14. Yoshida, K., and Inoue, I. (2004) Regulation of the ATR activator TopBP1 to sites of DNA damage. J. Biol. Chem. 279, 19859–19867
15. Wardlaw, C. P., Carr, A. M., and Oliver, A. W. (2014) TopBP1 mediates mutant p53 gain of function through NF-Y and p63/p73. Mol. Cell Biol. 31, 4464–4481
16. Wu, D. P., Yan, X. B., Liu, L. G., Tian, C., Han, K., Zhang, H., and Min, D. L. (2017) TopBP1 promotes malignant progression and correlates with poor prognosis in osteosarcoma. Eur. Rev. Med. Pharmacol. Sci. 21, 4022–4031
17. Chowdhury, P., Lin, G. E., Liu, K., Song, Y., Lin, F. T., and Lin, W. C. (2014) Targeting TopBP1 at a convergent point of multiple oncogenic pathways for cancer therapy. Nat. Commun. 5, 5476
18. Andegeko, Y., Moyal, L., Mittelman, L., Tsarfaty, I., Shiloh, Y., and Rotman, G. (2001) Nuclear retention of ATM at sites of DNA double strand breaks. J. Biol. Chem. 276, 38224–38230
19. Hintzsche, H., Montag, H., and Stopper, H. (2018) Induction of micro-nuclei by four cytostatic compounds in human hematopoietic stem cells and human lymphoblastoid TK6 cells. Sci. Rep. 8, 3371
20. Thomas, P., and Fenech, M. (2011) Cytokinesis-block micronucleus assay in lymphocytes. Methods Mol. Biol. 682, 217–234
21. Cancer Genome Atlas Research, N. (2015) The molecular taxonomy of primary prostate cancer. Cell 163, 1011–1025
22. Cancer Genome Atlas Research, N., Kandoth, C., Schultz, N., Cerny, A., D., Akbani, R., Liu, Y., Shen, H., Robertson, A. G., Pashtan, I., Shen, R., Benz, C. C., Yao, C., Laird, P. W., Ding, L., Zhang, W., et al. (2013) Integrated genomic characterization of endometrial carcinoma. Nature 497, 67–73
23. Lam, M. H., Liu, Q., Ellidge, S. J., and Rosen, J. M. (2004) Chk1 is haploinsufficient for multiple functions critical to tumor suppression. Cancer Cell 6, 45–59
24. Lewis, K. A., Mullaney, S., Thomas, B., Chien, J., Loewen, R., Shridhar, V., and Cliby, W. A. (2005) Heterozygous ATR mutations in mismatch repair-deficient cancer cells have functional significance. Cancer Res. 65, 7091–7095